Capmatinib vs Savolitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline
Capmatinib
Marketed by Novartis and partners
NCT04427072 · Phase 3 · terminated
This randomized, open-label trial compared capmatinib to docetaxel in patients with MET exon 14-mutant lung cancer, but enrolled only 22 participants (15 on capmatinib, 7 on docetaxel) before the sponsor terminated the study early. Median progression-free survival was numerically longer with capmatinib (6.1 vs 4.1 months), but the confidence intervals were wide and overlapping and no formal statistical test was reported, so this severely underpowered trial cannot reliably show whether capmatinib truly outperformed docetaxel.
Next expected readout: April 2027 · NCT05488314 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months (unclear)
Result source: NCT04427072
Savolitinib · Orpathys
Marketed by AstraZeneca and partners
NCT05015608 · Phase 3 · completed
The trial randomized 216 participants to savolitinib plus osimertinib or active chemotherapy, but treatment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT04322890 (registry estimate)
Reported efficacy
Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib. (Approximately 36.5 months post first subject randomized): SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib. (met)
Result source: NCT05261399
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Capmatinib
- 6.1 vs 4.1vs DocetaxelNCT04427072
4 other results
- 6.1 vs 3.6 NCT04427072
- 5.1 NCT01610336
- 5.5 NCT01610336
- 5.5 NCT02750215
- Savolitinib
- 8.2 vs 4.5avs chemotherapyNCT05015608
OS, median
- Capmatinib
- 12.5 vs 13.6vs DocetaxelNCT04427072
17 other results
- 12.3 NCT01610336
- 15.2 NCT01610336
- 10.6 NCT02414139
- 7.5 NCT02414139
- 10.2 NCT02414139
- 9.5 NCT02414139
- 13.6 NCT02414139
- 16.8 NCT02414139
- 9.6 NCT02414139
- 20.8 NCT02414139
- 25.9 NCT02414139
- 21.4 NCT02414139
- 21.4 NCT02414139
- 25.2 NCT04677595
- 15.8 NCT04677595
- 11.3 NCT02750215
- 4.1 NCT02414139
- Savolitinib
- —Not posted · NCT04923945
ORR
- Capmatinib
- 53.3% vs 0%vs DocetaxelNCT04427072
30 other results
- 46.7% vs 14.3% NCT04427072
- 29% NCT02414139
- 11.9% NCT02414139
- 9.3% NCT02414139
- 6.7% NCT02414139
- 40.6% NCT02414139
- 44% NCT02414139
- 40% NCT02414139
- 67.9% NCT02414139
- 51.6% NCT02414139
- 68.8% NCT02414139
- 68.3% NCT02414139
- 53.3% NCT04677595
- 38.1% NCT04677595
- 10% NCT02750215
- 0% NCT02414139
- 27.5% NCT02414139
- 7.1% NCT02414139
- 9.3% NCT02414139
- 3.3% NCT02414139
- 43.5% NCT02414139
- 44% NCT02414139
- 40% NCT02414139
- 60.7% NCT02414139
- 45.2% NCT02414139
- 56.3% NCT02414139
- 58.3% NCT02414139
- 66.7% NCT04677595
- 33.3% NCT04677595
- 0% NCT02414139
- Savolitinib
- 62.1%abNCT04923945
1 other result
- 39.2% NCT04923945
Duration of response, median
- Capmatinib
- 9.9 vs 3.1vs DocetaxelNCT04427072
34 other results
- 12.6 NCT04427072
- 5.6 NCT01610336
- 5.6 NCT01610336
- 8.3 NCT02414139
- 9.7 NCT02414139
- 12.6 NCT02414139
- 16.6 NCT02414139
- 9.7 NCT02414139
- 16.6 NCT02414139
- 6.8 NCT02414139
- 8.3 NCT02414139
- 15.2 NCT02414139
- 8.4 NCT02414139
- 24.9 NCT02414139
- 9.7 NCT02414139
- 7.5 NCT02414139
- 9.1 NCT02414139
- 9.7 NCT02414139
- 13.8 NCT02414139
- 14.0 NCT02414139
- 7.1 NCT04677595
- 15.8 NCT04677595
- 4.2 NCT02414139
- 6.9 NCT02414139
- 19.5 NCT02414139
- 14.6 NCT02414139
- 8.5 NCT04677595
- 9.8 NCT04677595
- 11.2 NCT04677595
- 4.2 NCT04677595
- 6.4 NCT04677595
- 19.6 NCT04677595
- 6.9 NCT02414139
- 3.8 NCT02750215
- Savolitinib
- —Not posted · NCT04923945
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Capmatinib: 5 of 5 rows · Savolitinib: 1 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Capmatinib Rows use multiple source trials | Savolitinib Rows use multiple source trials |
|---|---|---|
| ORR responder rate · % of participants No placebo or comparator arm | 29% (n=69)a,b,c,d NCT02414139 · Phase 2 show 23 more doses27.5% (n=69) NCT02414139 · Phase 2 11.9% (n=42) NCT02414139 · Phase 2 7.1% (n=42) NCT02414139 · Phase 2 9.3% (n=54) NCT02414139 · Phase 2 9.3% (n=54) NCT02414139 · Phase 2 6.7% (n=30) NCT02414139 · Phase 2 3.3% (n=30) NCT02414139 · Phase 2 44% (n=100) NCT02414139 · Phase 2 · combination 44% (n=100) NCT02414139 · Phase 2 · combination 40.6% (n=69) NCT02414139 · Phase 2 43.5% (n=69) NCT02414139 · Phase 2 40% (n=15) NCT02414139 · Phase 2 40% (n=15) NCT02414139 · Phase 2 68.3% (n=60) NCT02414139 · Phase 2 · combination 58.3% (n=60) NCT02414139 · Phase 2 · combination 67.9% (n=28) NCT02414139 · Phase 2 60.7% (n=28) NCT02414139 · Phase 2 0% (n=3) NCT02414139 · Phase 2 0% (n=3) NCT02414139 · Phase 2 51.6% (n=31) NCT02414139 · Phase 2 45.2% (n=31) NCT02414139 · Phase 2 68.8% (n=32) NCT02414139 · Phase 2 56.3% (n=32) NCT02414139 · Phase 2 | 39.2%a,b,c,d NCT04923945 · Phase 3 · sponsor-reported, not registry data show 1 more dose62.1% NCT04923945 · Phase 3 · sponsor-reported, not registry data |
| Dropout rate | n/a: no completion milestoneCapmatinibe NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 show 37 more results—Capmatinib (On-treatment) NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 —Capmatinib Extension Crossover Tre NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 n/a: no completion milestoneCohort 1a: Pre-treated Patients Wi NCT02414139 · Phase 2 n/a: no completion milestoneCohort 1b: Pre-treated Patients Wi NCT02414139 · Phase 2 n/a: no completion milestoneCohort 2: Pre-treated Patients Wit NCT02414139 · Phase 2 n/a: no completion milestoneCohort 3: Pre-treated Patients Wit NCT02414139 · Phase 2 n/a: no completion milestoneCohort 4: Pre-treated Patients Wit NCT02414139 · Phase 2 n/a: no completion milestoneCohort 5a: Treatment-naïve Patient NCT02414139 · Phase 2 n/a: no completion milestoneCohort 5b: Treatment-naïve Patient NCT02414139 · Phase 2 n/a: no completion milestoneCohort 6.1 (Expansion of Cohort 1a NCT02414139 · Phase 2 n/a: no completion milestoneCohort 6.2 (Expansion of Cohort 4) NCT02414139 · Phase 2 n/a: no completion milestoneCohort 7 (Expansion of Cohort 5b): NCT02414139 · Phase 2 86.7%Cohort 1 NCT04677595 · Phase 2 · registry result, not featured evidence 90.5%Cohort 2 NCT04677595 · Phase 2 · registry result, not featured evidence 0% NCT02750215 · Phase 2 · registry result, not featured evidence —800 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone800 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —600 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone600 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone400 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone200 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone200 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone200 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —100 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination | — |
| Discontinued due to AEs | 20%Capmatinibe NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 show 37 more results—Capmatinib (On-treatment) NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 —Capmatinib Extension Crossover Tre NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 15.9%Cohort 1a: Pre-treated Patients Wi NCT02414139 · Phase 2 14.3%Cohort 1b: Pre-treated Patients Wi NCT02414139 · Phase 2 14.8%Cohort 2: Pre-treated Patients Wit NCT02414139 · Phase 2 16.7%Cohort 3: Pre-treated Patients Wit NCT02414139 · Phase 2 20.3%Cohort 4: Pre-treated Patients Wit NCT02414139 · Phase 2 20%Cohort 5a: Treatment-naïve Patient NCT02414139 · Phase 2 21.4%Cohort 5b: Treatment-naïve Patient NCT02414139 · Phase 2 33.3%Cohort 6.1 (Expansion of Cohort 1a NCT02414139 · Phase 2 19.4%Cohort 6.2 (Expansion of Cohort 4) NCT02414139 · Phase 2 25%Cohort 7 (Expansion of Cohort 5b): NCT02414139 · Phase 2 13.3%Cohort 1 NCT04677595 · Phase 2 · registry result, not featured evidence 28.6%Cohort 2 NCT04677595 · Phase 2 · registry result, not featured evidence — NCT02750215 · Phase 2 · registry result, not featured evidence —800 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 14.3%800 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —600 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 0%600 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 15.1%400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 8.3%400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 0%400 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 12.8%400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 25%400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 25%200 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 0%200 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 0%200 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —100 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 0%100 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination | — |
| Serious AEs | —Capmatinibe NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 show 37 more results20%Capmatinib (On-treatment) NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 20%Capmatinib Extension Crossover Tre NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 —Cohort 1a: Pre-treated Patients Wi NCT02414139 · Phase 2 —Cohort 1b: Pre-treated Patients Wi NCT02414139 · Phase 2 —Cohort 2: Pre-treated Patients Wit NCT02414139 · Phase 2 —Cohort 3: Pre-treated Patients Wit NCT02414139 · Phase 2 —Cohort 4: Pre-treated Patients Wit NCT02414139 · Phase 2 —Cohort 5a: Treatment-naïve Patient NCT02414139 · Phase 2 —Cohort 5b: Treatment-naïve Patient NCT02414139 · Phase 2 —Cohort 6.1 (Expansion of Cohort 1a NCT02414139 · Phase 2 —Cohort 6.2 (Expansion of Cohort 4) NCT02414139 · Phase 2 —Cohort 7 (Expansion of Cohort 5b): NCT02414139 · Phase 2 46.7%Cohort 1 NCT04677595 · Phase 2 · registry result, not featured evidence 66.7%Cohort 2 NCT04677595 · Phase 2 · registry result, not featured evidence 10% NCT02750215 · Phase 2 · registry result, not featured evidence 42.9%800 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —800 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 60%600 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —600 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 22.6%400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 33.3%400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 33.3%400 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 40.4%400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 37.5%400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 0%200 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 28.6%200 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 71.4%200 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 20%100 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —100 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination | — |
| Most frequent reported AEs | e oedema peripheral 66.7% vomiting 40% cough 33.3% NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 show 15 more resultsalopecia 80% anaemia 60% asthenia 40% NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3 hypoalbuminaemia 60% hypocalcaemia 53.3% alanine aminotransferase increased 33.3% NCT04677595 · Phase 2 · registry result, not featured evidence hypocalcaemia 52.4% oedema peripheral 47.6% hypoalbuminaemia 42.9% NCT04677595 · Phase 2 · registry result, not featured evidence 800 mg Cap QD vomiting 100% nausea 85.7% decreased appetite 57.1% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 600 mg Cap BID cough 60% decreased appetite 60% hypoproteinaemia 40% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 400 mg Cap BID hypoalbuminaemia 43.4% anaemia 34% oedema peripheral 28.3% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 400 mg Cap BID hypoalbuminaemia 58.3% blood bilirubin increased 41.7% amylase increased 33.3% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 400 mg Cap QD nausea 50% cough 33.3% oedema peripheral 33.3% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 400 mg Tab BID nausea 55.3% oedema peripheral 44.7% decreased appetite 40.4% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 400 mg Tab BID decreased appetite 37.5% diarrhoea 37.5% headache 37.5% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 200 mg Cap BID diarrhoea 75% hypoalbuminaemia 75% anaemia 50% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 200 mg Cap QD back pain 57.1% rash 42.9% vomiting 42.9% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 200 mg Tab BID nausea 71.4% dermatitis acneiform 57.1% cystitis 42.9% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 100 mg Cap QD constipation 60% pruritus 60% amylase increased 40% NCT01610336 · Phase 2 · registry result, not featured evidence · combination | — |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for 35 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Capmatinib
show 1 more result
show 22 more results
show 37 more results
show 1 more result
show 1 more result
show 2 more results
+ 394 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Capmatinib's landscape · Savolitinib's landscape